<DOC>
	<DOC>NCT00428948</DOC>
	<brief_summary>This study's purpose is to evaluate the long-term safety and efficacy of tolvaptan versus placebo in patients with ADPKD.</brief_summary>
	<brief_title>Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD</brief_title>
	<detailed_description>The current study will evaluate whether tolvaptan will be potentially beneficial, while maintaining an adequate safety profile, by reducing the rate of total renal volume increase, while impacting the onset, severity and progression of other important consequences of ADPKD.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>GFR estimated at ≥60 mL/ min Diagnosis of ADPKD and rapidly progressive kidney growth (total volume ≥750 cc) by Magnetic Resonance Imaging (MRI) at randomization Legal adult age and able to give Informed Consent Willingness to comply with reproductive precautions if female Prior exposure to tolvaptan or other experimental PKD therapies Currently taking medication for purpose of affecting PKD cysts Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods In the opinion of the study investigator or sponsor may present a safety risk or confound study objectives Patients who are unlikely to adequately comply with study procedures Patients having contraindications to MRI Patients taking medications or having any illnesses likely to affect ADPKD outcomes.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>Polycystic</keyword>
	<keyword>kidney</keyword>
	<keyword>ADPKD (Autosomal Dominant Polycystic Kidney Disease)</keyword>
</DOC>